Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 20 Earnings per Share (Diluted) is A$0.00 as of Jun. 2026. GuruFocus rates ASX:S66 with a GF Score™ of 20/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,536 Consumer Packaged Goods companies, Star Combo Pharma ranks worse than 65104.1% on this metric.
Star Combo Pharma's EPS (Basic) for the
six
months ended in Jun. 2026 was A$-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.00.
During the past 10 years, Star Combo Pharma's highest 3-Year average EPS without NRI Growth Rate was 169.20% per year. The lowest was -20.50% per year. And the median was 5.90% per year.
Star Combo Pharma (ASX:S66) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Star Combo Pharma Earnings per Share (Diluted) Related Terms
Star Combo Pharma Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma Earnings per Share (Diluted) Chart
ASX:S66 vs PG, CL, EL: Earnings per Share (Diluted) Comparison
For the Household & Personal Products subindustry, Star Combo Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's PE Ratio distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's PE Ratio falls into.
Star Combo Pharma Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Star Combo Pharma's Earnings Per Share (Diluted) for the fiscal year that ended in Jun. 2026 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of A$0.00 mean?
Star Combo Pharma (ASX:S66) has a Earnings per Share (Diluted) of A$0.00 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #999999 out of 1536 companies in the Consumer Packaged Goods industry.
Is Star Combo Pharma's Earnings per Share (Diluted) too high?
Star Combo Pharma's current Earnings per Share (Diluted) is A$0.00. Based on the distribution chart, Star Combo Pharma ranks #999999 out of 1536 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Earnings per Share (Diluted) compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #999999 out of 1536 companies for Earnings per Share (Diluted). This places Star Combo Pharma in the lower half of its industry. The industry median Earnings per Share (Diluted) is 7.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Consumer Packaged Goods company?
The median Earnings per Share (Diluted) among Consumer Packaged Goods companies is 7.40, based on 1,536 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Earnings per Share (Diluted) is 7.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Earnings per Share (Diluted) is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current Earnings per Share (Diluted) is A$0.00. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Earnings per Share (Diluted) is A$0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Earnings per Share (Diluted): A$0.00
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
